{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0071940\nAge: 71\nGender: Male\nSample ID: P-0071940-T01-IM7\nGene Panel: IMPACT505\nCancer Type: Pancreatic Adenocarcinoma\nSample Type: Primary\nTumor Purity: 10.0%\n=============\nDNA Variants:\nKRAS c.33_35delinsCGT (p.G12V) - in 4.00% of 350 reads\nTP53 c.577C>A (p.H193N) - in 3.00% of 755 reads\nCNA Data:\nNo CNA data found.\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Pancreatic Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic or unresectable\",\n    \"Drug Name\": \"FOLFIRINOX (fluorouracil, irinotecan, oxaliplatin, leucovorin)\",\n    \"Prior Treatment or Resistance Status\": \"First-line treatment\",\n    \"Genomic Features\": \"KRAS G12V mutation (not directly targetable, but relevant for prognosis and potential clinical trial considerations)\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021523s000lbl.pdf\"\n  }\n}"
}